Compounds tracked
7 + 12
profiles · pipeline
Citations indexed
240+
PubMed-linked
Last update
2026.05
rolling editorial
Editorial stance
independent
no vendor ties

Featured compound profiles

All compounds →
EDITORIAL POSITION

Why we read the pipeline differently.

Most peptide coverage online is one of two things: cosmetic-grade marketing copy from compounding pharmacies, or thread-based folklore from forum culture. Neither is wrong on every point and neither is right on most.

Revolutionary Peptides reads the actual translational pipeline — the IND filings, the conference abstracts, the pre-clinical animal data, the Phase I tolerability work — and translates it into compound coverage that biohackers, longevity researchers, and early-stage adopters can actually use to make decisions.

We name our author. We cite our work. We hedge where the data hedges. And we maintain zero vendor relationships — no affiliate deals, no compounding-pharmacy sponsorships, no "preferred supplier" lists.

Read the editorial mission →

PIPELINE
Now tracking 12 next-gen candidates

Including Selank, Semax, Pinealon, Cerebrolysin fractions, PT-141, melanotan derivatives, and four undisclosed cyclic peptides in Phase I tolerability.

View tracker →

SAFETY
Conservative-first protocols

Every protocol on this site starts at the lowest tolerated published dose. Read our screening framework before you read anything else.

Safety guide →

Start here.

If you've never worked with research peptides, these four pages cover the entire conceptual foundation — biochemistry, dosing, handling, and safety.